Co-Diagnostics, Inc. (CODX) has a negative trailing P/E of 0.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -2,592.26%, forward earnings yield 476.19%.
Criteria proven by this page:
Overall SharesGrow Score: 45/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -33.3 | 6.00 | -21.46 | 0.00 | - |
| 2017 | -4.2 | -0.02 | 7.51 | 3,776.46 | - |
| 2018 | -3.0 | 0.14 | -17.57 | 466.09 | - |
| 2019 | -2.4 | 0.09 | 8.63 | 69.76 | - |
| 2020 | 5.8 | -0.05 | 3.73 | 3.33 | - |
| 2021 | 7.0 | 0.00 | 1.92 | 2.63 | - |
| 2022 | -5.6 | 0.04 | 0.69 | 2.32 | - |
| 2023 | -1.1 | -0.01 | 0.45 | 5.73 | - |
| 2024 | -0.6 | -0.18 | 0.42 | 5.81 | - |
| 2025 | -0.1 | 0.03 | 0.33 | 16.13 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.17 | $0.00 | $-1.93M | - |
| 2017 | $-0.63 | $7.66K | $-6.96M | -90827.9% |
| 2018 | $-0.50 | $39.91K | $-6.27M | -15714.3% |
| 2019 | $-0.36 | $214.97K | $-6.07M | -2823.2% |
| 2020 | $1.52 | $74.55M | $42.48M | 57% |
| 2021 | $1.23 | $97.89M | $36.66M | 37.5% |
| 2022 | $-0.45 | $34.22M | $-14.24M | -41.6% |
| 2023 | $-1.20 | $6.81M | $-35.33M | -518.7% |
| 2024 | $-1.24 | $3.92M | $-37.64M | -961.4% |
| 2025 | $-35.25 | $622.49K | $-46.9M | -7533.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-12.15 | $-12.17 – $-12.13 | $576.2K | $575.45K – $576.95K | 1 |
| 2027 | $-12.00 | $-12.02 – $-11.98 | $17.19M | $17.16M – $17.21M | 1 |
| 2028 | $-6.90 | $-6.91 – $-6.89 | $59.36M | $59.36M – $59.36M | 1 |
| 2029 | $6.60 | $6.59 – $6.61 | $136.59M | $136.41M – $136.77M | 1 |
